LCDX Caliber Imaging and Diagnostics Inc (CE)

Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., will exhibit a poster on confocal microscopy at the Society of Cosmetic Chemists 2013 Annual Scientific Meeting and Technology Showcase, to be held December 12-13 in New York, NY.

The poster, titled "In Vivo Reflectance and Fluorescence Confocal Microscopy for Quantitative Cutaneous Measurements," was co-authored by Christi Alessi Fox, Caliber I.D.'s Director of Clinical Activities and Allison Herschell, Clinical Associate at Caliber I.D. The poster presents basic applications of reflectance and fluorescence confocal microscopy for evaluating specific features of the skin, and describes the methodology for capturing images and performing calculations.

L. Michael Hone, Chief Executive Officer of Caliber I.D., said, "Our VivaScope® systems have played an important role in testing and analysis for the cosmetics industry. By using Caliber's VivaScope technology to substantiate claims, our clients have shortened their product-development cycle. We look forward to presenting the poster to this group of cosmetic scientists who are focused on learning about new research in the industry, and communicating how our technology can help them in their roles."

About the Society of Cosmetic Chemists

Dedicated to the advancement of cosmetic science, the Society strives to increase and disseminate scientific information through meetings and publications. By promoting research in cosmetic science and industry, and by setting high ethical, professional and educational standards, it reaches its goal of improving the qualifications of cosmetic scientists. Its mission is to further the interests and recognition of cosmetic scientists while maintaining the confidence of the public in the cosmetic and toiletries industry.

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope significantly improves outcomes and reduces costs, allowing physicians to quickly detect cancerous lesions that appear benign. VivaScope dramatically reduces the need for expensive, painful and time-consuming biopsies. VivaScope also has significant applications in testing and analysis in the cosmetics industry. For more information about Caliber I.D. and its products, please visit www.caliberid.com.

VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.

CONTACT: Richard Pulsifer
         Chief Financial Officer
         (617) 348-9821
         
         Investor Relations:
         Dian Griesel Int'l.
         Cheryl Schneider
         (212) 825-3210
         cschneider@dgicomm.com
         
         Public Relations:
         Dian Griesel Int'l.
         Susan Forman or Laura Radocaj
         (212) 825-3210
         sforman@dgicomm.com
         lradocaj@dgicomm.com